Literature DB >> 19623680

Changing pattern in the prescription of biological treatment in rheumatoid arthritis. A 7-year follow-up of 1839 patients in southern Sweden.

M K Söderlin1, P Geborek.   

Abstract

OBJECTIVE: To study prescription patterns of biological treatment in rheumatoid arthritis (RA) patients in southern Sweden, a region with no formal or economic restrictions for the use of biological treatment in rheumatological diseases. Specifically, we studied conformity with the national Swedish guidelines for biologics in RA.
METHODS: Rheumatologists in southern Sweden contribute to a voluntary register on the use of biologics in treating arthritis patients (the South Swedish Arthritis Treatment Group (SSATG)). This register covers .90% of all the prescriptions of biologics for arthritis patients in the region. The treatment of 1839 patients (2704 treatment occasions) was recorded in the SSATG register during 1999-2006. Baseline characteristics were analysed.
RESULTS: Baseline Health Assessment Questionnaire(HAQ) scores and Disease Activity Scores (DASs)decreased significantly between 1999 and 2006, but disease activity remained high in RA patients. RA patients were treated with biologics earlier, but only 16% of the patients received biologics within 2 years of disease onset in 2006. The percentage of RA patients who were prescribed biologics after only one previous non-biological DMARD (disease-modifying anti-inflammatory rheumatic drug) was 27% in 2006. Thirty-five per cent of all RA patients changed from one biological treatment to another.
CONCLUSIONS: Baseline DASs in RA patients remained high at the start of biological treatment. The national Swedish guidelines for the prescription of biologics in RA were followed. More patients with early RA were treated with biologics. The proportion of RA patients changing from one biological drug to another increased.

Entities:  

Mesh:

Year:  2008        PMID: 19623680     DOI: 10.1136/ard.2007.070714

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  11 in total

1.  Switching profiles in a population-based cohort of rheumatoid arthritis receiving biologic therapy: results from the KOBIO registry.

Authors:  Dong-Jin Park; Sung Jae Choi; Kichul Shin; Hyoun-Ah Kim; Yong-Beom Park; Seong Wook Kang; Seung-Ki Kwok; Seong-Kyu Kim; Eon Jeong Nam; Yoon-Kyoung Sung; Jaejoon Lee; Chang Hoon Lee; Chan Hong Jeon; Shin-Seok Lee
Journal:  Clin Rheumatol       Date:  2017-02-27       Impact factor: 2.980

2.  The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice.

Authors:  Ingrid Lekander; Fredrik Borgström; Jörgen Lysholm; Ronald F van Vollenhoven; Staffan Lindblad; Pierre Geborek; Gisela Kobelt
Journal:  Eur J Health Econ       Date:  2012-09-19

3.  Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists.

Authors:  Hilbert S de Vries; Martijn G H van Oijen; Rieke J B Driessen; Elke M G J de Jong; Marjonne C W Creemers; Wietske Kievit; Dirk J de Jong
Journal:  Br J Clin Pharmacol       Date:  2011-01       Impact factor: 4.335

Review 4.  The importance of rheumatology biologic registries in Latin America.

Authors:  Maria de la Vega; Hellen M da Silveira de Carvalho; Lucio Ventura Ríos; Maria V Goycochea Robles; Gustavo C Casado
Journal:  Rheumatol Int       Date:  2012-12-23       Impact factor: 2.631

5.  Evaluating the efficacy of sequential biologic therapies for rheumatoid arthritis patients with an inadequate response to tumor necrosis factor-α inhibitors.

Authors:  Regina Rendas-Baum; Gene V Wallenstein; Tamas Koncz; Mark Kosinski; Min Yang; John Bradley; Samuel H Zwillich
Journal:  Arthritis Res Ther       Date:  2011-02-16       Impact factor: 5.156

6.  Increased risk of revision for infection in rheumatoid arthritis patients with total hip replacements.

Authors:  Johannes Cornelis Schrama; Anne M Fenstad; Håvard Dale; Leif Havelin; Geir Hallan; Søren Overgaard; Alma B Pedersen; Johan Kärrholm; Göran Garellick; Pekka Pulkkinen; Antti Eskelinen; Keijo Mäkelä; Lars B Engesæter; Bjørg-Tilde Fevang
Journal:  Acta Orthop       Date:  2015-03-17       Impact factor: 3.717

7.  Hospitalization for musculoskeletal disorders in rheumatoid arthritis patients: a population-based study.

Authors:  Marina Amaral de Ávila Machado; Sasha Bernatsky; Louis Bessette; Hacene Nedjar; Elham Rahme
Journal:  BMC Musculoskelet Disord       Date:  2016-07-19       Impact factor: 2.362

8.  Continuation of TNF blockade in patients with inflammatory rheumatic disease. An observational study on surgical site infections in 1,596 elective orthopedic and hand surgery procedures.

Authors:  Elisabet Berthold; Pierre Geborek; Anders Gülfe
Journal:  Acta Orthop       Date:  2013-09-16       Impact factor: 3.717

9.  Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab.

Authors:  M Neovius; E V Arkema; H Olsson; J K Eriksson; L E Kristensen; J F Simard; J Askling
Journal:  Ann Rheum Dis       Date:  2013-11-27       Impact factor: 19.103

10.  Comparisons between comorbid conditions and health care consumption in rheumatoid arthritis patients with or without biological disease-modifying anti-rheumatic drugs: a register-based study.

Authors:  Karin Bengtsson; Lennart T H Jacobsson; Barbro Rydberg; Göran Kvist; Tomas Torstenson; Mats Dehlin; Elisabet Hilme; Anna Lindhé; Susanna Maria Wallerstedt; Helena Forsblad-d'Elia
Journal:  BMC Musculoskelet Disord       Date:  2016-12-12       Impact factor: 2.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.